Table 2.

Histopathologic analysis of mice treated with estriol or placebo

EAE mice treatmentNo. demyelinated lesionsNo. inflammatory lesions
Histopathologic analysis of mice given 90-day-release implants of estriol (5 or 15 mg) or placebo before the adoptive transfer of myelin basic protein-specific cells to induce EAE. Three mice were examined in each treatment group. Two blocks of lumbosacral spinal cord from each mouse, separated spatially by 1 to 2 mm, underwent semiquantitative assessment for demyelination and inflammation. Inflammation occurred in perivascular locations. In addition to a decrease in demyelination and inflammation, estriol-treated mice demonstrated markedly decreased meningeal infiltration. Mice were sacrificed at the day of maximal clinical disease difference between placebo and estriol treatment, with placebo mouse 1 at clinical grade 2.5, placebo mice 2 and 3 at clinical grade 4.0, and all three 5-mg estriol-treated mice and all three 15-mg estriol-treated mice at clinical grade 0.
EAE = experimental autoimmune encephalomyelitis.
Placebo treated
Placebo 195
Placebo 21321
Placebo 31012
Estriol treated, 5 mg
Estriol 110
Estriol 200
Estriol 300
Estriol treated, 15 mg
Estriol 100
Estriol 200
Estriol 300